litlas
Log inCreate account

David H. Raulet

Active 1979–2026

125
Papers
36,767
Citations
97
h-index
123
i10-index

Citations

Citations per year for David H. Raulet1980: 6 citations1981: 6 citations1982: 11 citations1983: 8 citations1984: 11 citations1985: 17 citations1986: 53 citations1987: 78 citations1988: 76 citations1989: 91 citations1990: 106 citations1991: 97 citations1992: 118 citations1993: 188 citations1994: 209 citations1995: 192 citations1996: 166 citations1997: 174 citations1998: 178 citations1999: 183 citations2000: 152 citations2001: 202 citations2002: 267 citations2003: 260 citations2004: 342 citations2005: 464 citations2006: 484 citations2007: 354 citations2008: 448 citations2009: 322 citations2010: 321 citations2011: 321 citations2012: 282 citations2013: 314 citations2014: 335 citations2015: 286 citations2016: 228 citations2017: 275 citations2018: 336 citations2019: 817 citations2020: 1,070 citations2021: 960 citations2022: 816 citations2023: 621 citations2024: 934 citations2025: 525 citations2026: 12 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,431 citing papers, 34.3% of this breakdownChina: 1,426 citing papers, 11.1% of this breakdownFrance: 730 citing papers, 5.7% of this breakdownGermany: 709 citing papers, 5.5% of this breakdownUnited Kingdom: 682 citing papers, 5.3% of this breakdownItaly: 556 citing papers, 4.3% of this breakdownCanada: 435 citing papers, 3.4% of this breakdownJapan: 429 citing papers, 3.3% of this breakdownAustralia: 367 citing papers, 2.8% of this breakdownSwitzerland: 272 citing papers, 2.1% of this breakdownNetherlands: 227 citing papers, 1.8% of this breakdownSpain: 226 citing papers, 1.7% of this breakdown
0%34.3%Other 18.7%

Institutions

Fields

  • Immunology and Microbiology59.1%
  • Medicine26%
  • Biochemistry, Genetics and Molecular Biology11.1%
  • Neuroscience1.3%
  • Engineering0.9%
  • Mathematics0.4%
  • Other1.2%

Topics

  • Immune Cell Function and Interaction18.8%
  • T-cell and B-cell Immunology12%
  • Immunotherapy and Immune Responses6.5%
  • CAR-T cell therapy research5.5%
  • Cancer Immunotherapy and Biomarkers3.8%
  • Immune cells in cancer3%
  • Other50.4%

Coauthors

All papers

Open in search
  1. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy

    Authors: Natalie K. Wolf, Djem Kissiov, David H. Raulet - Nature reviews. Immunology 2022 cited by 545

  2. Innate or Adaptive Immunity? The Example of Natural Killer Cells

    Authors: Éric Vivier, David H. Raulet, Alessandro Moretta, Michael A. Caligiuri, Laurence Zitvogel, Lewis L. Lanier, Wayne M. Yokoyama, Sophie Ugolini - Science 2011 cited by 2,757

  3. Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response

    Authors: Assaf Marcus, Amy J. Mao, Monisha Lensink-Vasan, LeeAnn Wang, Russell E. Vance, David H. Raulet - Immunity 2018 cited by 612

  4. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

    Authors: Joy Hsu, Jonathan J. Hodgins, Malvika Marathe, Chris J. Nicolai, Marie‐Claude Bourgeois‐Daigneault, Troy N. Trevino, Camillia S. Azimi, Amit Scheer, Haley E. Randolph, Thornton W. Thompson, Lily Zhang, Alexandre Iannello, Nikhita Mathur, Karen Jardine, Georgia Kirn, John C. Bell, Michael W. McBurney, David H. Raulet, Michele Ardolino - Journal of Clinical Investigation 2018 cited by 827

  5. NK cells mediate clearance of CD8 + T cell–resistant tumors in response to STING agonists

    Authors: Christopher J. Nicolai, Natalie K. Wolf, I-Chang Chang, Georgia Kirn, Assaf Marcus, Chudi Ndubaku, Sarah M. McWhirter, David H. Raulet - Science Immunology 2020 cited by 266

  6. SLC19A1 transports immunoreactive cyclic dinucleotides

    Authors: Rutger D. Luteijn, Shivam A. Zaver, Benjamin G. Gowen, Stacia K. Wyman, Nick E. Garelis, Liberty Onia, Sarah M. McWhirter, George E. Katibah, Jacob E. Corn, Joshua J. Woodward, David H. Raulet - Nature 2019 cited by 385

  7. Neutrophils Suppress Intraluminal NK Cell–Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells

    Authors: Asaf Spiegel, Mary W. Brooks, Samin Houshyar, Ferenc Reinhardt, Michele Ardolino, Evelyn Fessler, Michelle B. Chen, Jordan A. Krall, Jasmine DeCock, Ioannis K. Zervantonakis, Alexandre Iannello, Yoshiko Iwamoto, Virna Cortez‐Retamozo, Roger D. Kamm, Mikaël J. Pittet, David H. Raulet, Robert A. Weinberg - Cancer Discovery 2016 cited by 466

  8. Regulation of Ligands for the NKG2D Activating Receptor

    Authors: David H. Raulet, Stephan Gasser, Benjamin G. Gowen, Weiwen Deng, Heiyoun Jung - Annual Review of Immunology 2013 cited by 821

  9. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells

    Authors: Alexandre Iannello, Thornton W. Thompson, Michele Ardolino, Scott W. Lowe, David H. Raulet - The Journal of Experimental Medicine 2013 cited by 401

  10. Innate immune cells in the tumor microenvironment

    Authors: Ming O. Li, Natalie K. Wolf, David H. Raulet, Leila Akkari, Mikaël J. Pittet, Paulo C. Rodrı́guez, Rosandra N. Kaplan, Ariel Munitz, Zemin Zhang, Sijin Cheng, Nina Bhardwaj - Cancer Cell 2021 cited by 136

  11. Roles of the NKG2D immunoreceptor and its ligands

    Authors: David H. Raulet - Nature reviews. Immunology 2003 cited by 1,332

  12. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

    Authors: Stephan Gasser, Sandra Oršulić, Eric J. Brown, David H. Raulet - Nature 2005 cited by 1,278

  13. NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous Malignancy

    Authors: Nadia Guerra, Ying Xim Tan, Nathalie T. Joncker, Augustine Choy, Fermin Gallardo, Na Xiong, Susan Knoblaugh, Dragana Cado, Norman R. Greenberg, David H. Raulet - Immunity 2008 cited by 813

  14. Coordinated Induction by IL15 of a TCR-Independent NKG2D Signaling Pathway Converts CTL into Lymphokine-Activated Killer Cells in Celiac Disease

    Authors: Bertrand Meresse, Zhangguo Chen, Cezary Ciszewski, Maria Tretiakova, Govind Bhagat, Thomas Krausz, David H. Raulet, Lewis L. Lanier, Veronika Groh, Thomas A. Spies, Ellen C. Ebert, Peter H. Green, Bana Jabrì - Immunity 2004 cited by 833

  15. Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging

    Authors: Denise P. Muñoz, Steven M. Yannone, Anneleen Daemen, Yu Sun, Funda Vakar‐Lopez, Misako Kawahara, Adam Freund, Françis Rodier, Jennifer D. Wu, Pierre-Yves Desprez, David H. Raulet, Peter S. Nelson, Laura van ‘t Veer, Judith Campisi, Jean-Philippe Coppé - JCI Insight 2019 cited by 154

  16. Self-tolerance of natural killer cells

    Authors: David H. Raulet, Russell E. Vance - Nature reviews. Immunology 2006 cited by 577

  17. RAE1 Ligands for the NKG2D Receptor Are Regulated by STING-Dependent DNA Sensor Pathways in Lymphoma

    Authors: Adeline R. Lam, Nina Le Bert, Samantha S.W. Ho, Yu J. Shen, Melissa L.F. Tang, Gordon M. Xiong, J. Ludovic Croxford, Christine X. Koo, Ken J. Ishii, Shizuo Akira, David H. Raulet, Stephan Gasser - Cancer Research 2014 cited by 175

  18. Tumor-induced disruption of the blood-brain barrier promotes host death

    Authors: Jung Kim, Hsiu‐Chun Chuang, Natalie K. Wolf, Christopher J. Nicolai, David H. Raulet, Kaoru Saijo, David Bilder - Developmental Cell 2021 cited by 76

  19. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity

    Authors: Andreas Diefenbach, Eric R. Jensen, A. M. Jamieson, David H. Raulet - Nature 2001 cited by 1,065

  20. The Role of the NKG2D Immunoreceptor in Immune Cell Activation and Natural Killing

    Authors: A. M. Jamieson, Andreas Diefenbach, Christopher W. McMahon, Na Xiong, James R. Carlyle, David H. Raulet - Immunity 2002 cited by 629

  21. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors

    Authors: Michele Ardolino, Camillia S. Azimi, Alexandre Iannello, Troy N. Trevino, Lucas H. Horan, Lily Zhang, Weiwen Deng, Aaron M. Ring, Suzanne Fischer, K. Christopher García, David H. Raulet - Journal of Clinical Investigation 2014 cited by 192

  22. MHC Class I Deficiency: Susceptibility to Natural Killer (NK) Cells and Impaired NK Activity

    Authors: Nan‐Shih Liao, Mark Bix, Maarten Zijlstra, Rudolf Jaenisch, David H. Raulet - Science 1991 cited by 479

  23. Recognition of Tumors by the Innate Immune System and Natural Killer Cells

    Authors: Assaf Marcus, Benjamin G. Gowen, Thornton W. Thompson, Alexandre Iannello, Michele Ardolino, Weiwen Deng, Lin Wang, Nataliya Tovbis Shifrin, David H. Raulet - Advances in immunology 2014 cited by 364

  24. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice

    Authors: Mark Bix, Nan‐Shih Liao, Maarten Zijlstra, Janet M. Loring, Rudolf Jaenisch, David H. Raulet - Nature 1991 cited by 424